[Tree] FDA approval of Basilea Pharmaceutica's antibiotic, Ceftobiprole, Multidrug-resistant strains, Antibiotic resistance

Version 0.13 (2024-04-03 20:19:16.321000)

updates: FDA approval of Basilea Pharmaceutica's antibiotic ceftobiprole

  • ➔
Version 0.12 (2024-04-01 18:31:23.852000)

updates: Integration of new information about the AI model SyntheMol and its potential in generating new drugs for antibiotic-resistant bacteria

  • ➔
  • ➔
  • ➔
Version 0.11 (2024-03-28 22:23:20.046000)

updates: Integration of information about the economics of antibiotics and the Pasteur Act

  • ➔
  • ➔
Version 0.1 (2024-03-22 17:39:00.318000)

updates: New details on the AI model and its potential impact

  • ➔
  • ➔
Version 0.09 (2024-03-22 17:36:21.603000)

updates: AI model called SyntheMol developed by researchers at McMaster University and Stanford University can design new antibiotics to combat Acinetobacter baumannii

  • ➔
  • ➔
Version 0.08 (2024-03-22 17:32:07.249000)

updates: Development of AI model for antibiotic design

  • ➔
Version 0.07 (2024-03-02 09:47:30.289000)

updates: FDA approval for Indian antibiotic developed by Assamese scientist

  • ➔
Version 0.06 (2024-02-17 18:18:50.303000)

updates: Information about Kerala's AMR action plan in India

  • ➔
  • ➔
  • ➔
  • ➔
Version 0.05 (2024-02-17 15:18:33.570000)

updates: The report assesses the progress made by the 11 largest global economies in addressing AMR. It reveals that nearly 5 million deaths are associated with AMR every year worldwide, with a disproportionate impact on low and middle-income countries. Without action, AMR could cost the global economy as much as $3.4 trillion annually by 2023. The report emphasizes the need for innovative and novel antimicrobials to combat the growing resistance to existing drugs. The United Kingdom is recognized as the global leader in the fight against AMR, but the report highlights that more needs to be done by all countries to combat this threat.

  • ➔
  • ➔
  • ➔
Version 0.04 (2024-02-17 14:18:42.337000)

updates: Integrates the new report on the urgent need for global action against antimicrobial resistance and highlights the potential health and economic consequences of AMR

  • ➔
  • ➔
Version 0.03 (2024-01-29 05:22:40.585000)

updates: Deep learning discovery of new antibiotics

  • ➔
  • ➔
  • ➔
Version 0.02 (2024-01-15 10:44:24.617000)

updates: Integration of AI in drug development and creation of the 'reactome' platform

  • ➔
  • ➔
Version 0.01 (2023-12-20 19:52:41.741000)

updates: Integration of deep learning in antibiotic discovery

  • ➔
  • ➔
Version 0.0 (2023-11-22 17:14:50.055000)

updates:

  • ➔